Format

Send to

Choose Destination
Anticancer Res. 2017 Oct;37(10):5791-5795.

The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis.

Author information

1
Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan yokomatsumoto45@gmail.com.
2
Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan.

Abstract

BACKGROUND/AIM:

The purpose of this study was to assess the prognosis of small cell lung cancer (SCLC) based on the underlying pulmonary disease.

PATIENTS AND METHODS:

A total of 204 patients with SCLC were reviewed and categorized into three groups: normal, emphysema and fibrosis.

RESULTS:

The median overall survival duration (OS) in patients with normal lungs (n=57), with emphysema (n=105) and fibrosis (n=42) was 21.3, 16.4 and 10.8 months (p=0.063). In limited-stage disease (LD), the median OS in patients with fibrosis (7.4 months) was shorter than normal (52.7 months) or emphysema patients (26.4 months) (p=0.034). In extensive-stage disease (ED), the median OS in patients with fibrosis (12.7 months) was not significantly different from normal (11.4 months) or emphysema patients (13.5 months) (p=0.600).

CONCLUSION:

Patients with fibrosis had a poorer prognosis than normal or emphysema patients in LD-SCLC, but the coexistence of pulmonary fibrosis did not affect the prognostic outcomes in ED-SCLC.

KEYWORDS:

Acute lung injury; emphysema; interstitial pneumonitis; pulmonary fibrosis; small cell lung cancer

PMID:
28982903
DOI:
10.21873/anticanres.12021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center